Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 3, 2007, Pages 994-1001

  Mandal, Ardhendu K ^a   Das, Subhankar ^a   Basu, Mukul K ^a   Chakrabarti, Rohini N ^b   Das, Nirmalendu ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b Ashok Laboratory   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; FLAVONOID; LIPOSOME; QUERCETIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL SEPARATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; HISTOPATHOLOGY; KUPFFER CELL; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; LIVER MITOCHONDRION; LIVER NECROSIS; LIVER PROTECTION; MALE; MITOCHONDRIAL MEMBRANE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SATELLITE CELL; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTIOXIDANTS; ARSENITES; COLLAGEN; GALACTOSIDES; HYDROXYPROLINE; LIPID PEROXIDATION; LIPOSOMES; LIVER; LIVER CIRRHOSIS; MALE; MEMBRANE FLUIDITY; MITOCHONDRIA, LIVER; QUERCETIN; RATS; RATS, INBRED STRAINS; SODIUM COMPOUNDS;

EID: 33847158432     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.114215     Document Type: Article

References (36)

1. Budai M and Szoqvi M (2001) Liposomes as drug carrier systems: preparation, classification and therapeutic advantages of liposomes. Acta Pharm Hung 71:114-118.
2. Castro VM, Soderstrom M, Carlberg I, Widersten M, Platz A, and Mannervik B (1990) Differences among human tumor cell lines in the expression of glutathione transferases and other glutathione-linked enzymes. Carcinogen 11:1569-1576.
3. Chatterjee A, Das D, Mandal BK, Chowdhury TR, Samanta G, and Chakraborti D (1995) Arsenic in ground water in six districts of West Bengal, India: the biggest arsenic calamity in the world: I. Arsenic species in drinking water and urine of the affected people. Analyst 120:643-650.
4. Csanaky I and Gregus Z (2002) Species variations in the biliary and urinary excretion of arsenate, arsenite and their metabolites. Comp Biochem Physiol C Toxicol Pharmacol 131:355-365.
5. Das S, Santra A, Lahiri S, and Guha Mazumder DN (2005) Implications of oxidative stress and hepatic cytokine (TNF-alpha and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity. Toxicol Appl Pharmacol 204:18-26.
6. Datta N, Mukherjee S, Das L, and Das PK (2003) Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up regulation and T-cell activation. Eur J Immunol 33:1508-1518.
7. Du WD, Zhang YE, Zhai WR, and Zhou XM (1999) Dynamic changes of type cn, co and co collagen synthesis and distribution of collagen-producing cells in carbon-tetrachloride induced rat liver fibrosis. World J Gastroenterol 5:397-403.
8. Flora SJS, Dube SN, Arora U, Kannan GM, Shukla MK, and Malhotra PR (1995) Therapeutic potential of meso 2,3-dimer-captosuccinic acid or 2,3-dimercaptopropane 1-sulfonate in chronic arsenic intoxication in rats. Biometals 8:11.
9. Greenwel P, Dominguez-Rosals JA, Mavi G, Rivas-Estilla AM, and Rojkind M (2000) Hydrogen peroxide: a link between acetaldehyde-elicited alpha 1 (I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology 31:109-116.
10. Guha Mazumder DN, Das Gupta J, Santra A, Pal A, Ghosh A, and Sarker S (1998) Chronic arsenic toxicity in West Bengal: the worst calamity in the World. Ind Med Assoc 96:4-7.
11. Guha Mazumder DN, De BK, Santra A, Ghosh N, Das S, Lahiri S, and Das T (2001) Randomized placebo-controlled trial of 2,3-dimercapto-1-propanesulfonate (DMPS) in therapy of chronic arsenicosis due to drinking arsenic-contaminated water. Clin Toxicol 39:665-674.
12. Karim S, Bhandari U, Kumar H, Salam A, Siddiqui MAA, and Pillai KK (2001) Doxorubicin induced cardiotoxicity and its modulation by drugs. Ind J Pharm 33:203-207.
13. Kawakami S, Munakata C, Fumoto S, Yamashita F, and Hashida M (2001) Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs. J Pharm Sci 90:105-113.
14. Kessel M, Liu SX, Xu A, Santella R, and Hei TK (2002) Arsenic induces oxidative DNA damage in mammalian cells. Mol Cell Biochem 234-235:301-308.
15. Lee ES, Lee HE, Shin JY, Yoon S, and Moon JK (2003) The flavonoid Quercetin inhibits dimethyl nitrosamine-induced liver damage in rats. J Pharm Pharmacol 55:1169-1174.
16. Lin Y, Li HB, and Huang JT (2005) Following the fate of murine epidermal Stem cells in a syngeneic dermal equivalent in vivo. Zhonghua Zheng Xing Wai Ke Za Zhi 21:452-456.
17. Maiti S and Chatterjee AK (2000) Differential response of cellular antioxidant mechanism of liver and kidney to arsenic exposure and its relation to dietary protein deficiency. Environ Toxicol Pharm 8:227-235.
18. Manajit C, Kawakami S, Yamashita F, and Hashida M (2005) Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes. J Pharm Sci 94:2266-2275.
19. Mandal AK and Das N (2005) Sugar coated liposomal flavonoid: a unique formulation in combating carbontetrachloride induced hepatic oxidative damage. J Drug Target 13:305-315.
20. Mandal AK, Sinha J, Mandal S, Mukhopadhyay S, and Das N (2002) Targeting of liposomal flavonoid to liver in combating hepatocellular oxidative damage. Drug Deliv 9:181-185.
21. Mitra M, Mandal AK, Chatterjee TK, and Das N (2005) Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis. J Drug Target 13:285-293.
22. Moragon AC, De Lucas Garcia N, Encarnacion Lopez Fernandez M, Rodriguez-Manzaneque AS, and Jimenez Fraile JA (2005) Antioxidant enzymes, occupational stress and burnout in workers of a prehospitalary emergency service. Eur J Emerg Med 12:111-115.
23. Peres W, Tunon MJ, Collado PS, Herrmann S, Marroni N, and Gonzalez-Gallego J (2000) The flavonoid quercetin ameliorates liver damage in rats with biliary obstruction. J Hepatol 33:742-750.
24. Pi J, Yamauchi H, Kumagai Y, Sun G, Yoshida T, Aikawa H, Hopenhayn-Rich C, and Shimojo N (2002) Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect 110:331-336.
25. Ramos O, Carrizales L, Yanez L, Mejia J, Batres L, Ortiz D, and Diaz-Barry F (1995) Arsenic increased lipid peroxidation in rat tissues by a mechanism independent of glutathione levels. Environ Health Perspect 103:85-88.
26. Sarin SK, Sharma G, Banerjee S, Kathayat R, and Malhotra V (1999) Hepatic fibrogenesis using chronic arsenic ingestion: studies in a murine model. Ind J Exp Biol 37:147-151.
27. Sarkar S and Das N (2006) Mannosylated liposomal flavonoid in combating agerelated ischemia-reperfusion induced oxidative damage in rat brain. Mech Age Dev 127:391-397.
28. Sarkar S, Mandal S, Sinha J, Mukhopadhyay S, Das N, and Basu MK (2002) Quercetin: critical evaluation as an anti leishmanial agent in vivo in hamsters using different vesicular delivery modes. J Drug Target 10:573-578.
29. Sing D, Chander V, and Chopra K (2004) The effect of Quercetin, a biflavonoid on ischaemia/reperfusion induced renal injury in rats. Arch Med Res 35:484-494.
30. Sinha J, Das N, and Basu MK (2000) Targeting of glycoside grafted liposomes to specific hepatocellular sites. J Surface Sci Technol 16:200-209.
31. Stanton CR, Thibodeau R, Lankowski A, Shaw JR, Hamilton JW, and Stanton BA (2006) Arsenic inhibits CFTR-mediated chloride secretion by killifish (Fundulus heteroclitus) opercular membrane. Cell Physiol Biochem 17:269-278.
32. Styblo M, Del Razo LM, Vega L, Germolec DR, Le Cluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, and Thomas DJ (2000) Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74:289-299.
33. Testa R, Bindi P, Risso D, Borzone S, Caglieris S, Bardellini E, Grasso A, and Celle G (1993) Serum prolyl-hydroxylase as an index of fibrogenetic activity in chronic active hepatitis and cirrhosis. Eur J Gastroenterol Hepatol 5:103-107.
34. Tirmenstein MA and Nelson SD (1989) Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 31-hydroxyacetanilide, in mouse liver. J Biol Chem 264:9814-9819.
35. Tokyol C, Yilmaz S, Kahraman A, Cakar H, and Polat C (2006) The effects of desferrioxamine and quercetin on liver injury induced by hepatic ischaemia-reperfusion in rats. Acta Chir Belg 106:68-72.
36. Tyagi R, Lala S, Verma AK, Nandy AK, Mahato SB, Maitra A, and Basu MK (2005) Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J Drug Target 13:161-171.